Cyclooxygenase 2 Inhibition Exacerbates Palmitate-Induced Inflammation and Insulin Resistance in Skeletal Muscle Cells
Por:
Coll, T, Palomer, X, Blanco-Vaca, F, Escola-Gil, JC, Sanchez, RM, Laguna, JC, Vazquez-Carrera, M
Publicada:
1 feb 2010
Resumen:
Palmitate-induced inflammation is involved in the development of insulin resistance in skeletal muscle cells. Here we evaluated the effect of the saturated fatty acid palmitate and the monounsaturated fatty acid oleate on Toll-like receptors (TLR)-2 and -4 and cyclooxygenase 2 (COX-2) expression and examined whether the inhibition of this enzyme modulates fatty acid-induced inflammation. Skeletal muscle cells exposed to palmitate showed enhanced TLR-2 and COX-2mRNA levels, whereas oleate did not modify their expression. Palmitate-induced expression of these genes was dependent on nuclear factor (NF)-kappa B activation, because expression was reduced in the presence of the NF-kappa B inhibitor parthenolide. Co-incubation of palmitate-exposed cells with oleate also prevented the increase in the expression of TLR-2 and COX-2, through a mechanism that may involve activation of peroxisome proliferator-activated receptor-alpha (PPAR alpha) by this monounsaturated fatty acid. COX-2 inhibition by NS-398 enhanced IL-6 and TNF-alpha expression and IL-6 protein secretion induced by palmitate. NF-kappa B binding activity and TNF-alpha mRNA levels were enhanced in palmitate-exposed cells in the absence or in the presence of NS-398, whereas coincubation of palmitate-exposed cells with NS-398 and prostaglandin E-2 (PGE(2)) prevented these changes. In contrast, 12-lypoxygenase and cytochrome P450 hydroxylase pathways were not involved in these changes. Similarly, COX-2 inhibition impaired insulin-stimulated Akt phosphorylation and 2-deoxy-D-[C-14] glucose uptake in palmitate-exposed skeletal muscle cells, and this effect was abolished in the presence of PGE(2). These findings indicate that COX-2 activity, through the production of PGE(2), attenuates the fatty acid-induced inflammatory process and insulin resistance. (Endocrinology 151: 537-548, 2010)
Filiaciones:
Coll, T:
Univ Barcelona, Fac Pharm, Pharmacol Unit, Dept Pharmacol & Therapeut, E-08028 Barcelona, Spain
Univ Barcelona, Fac Pharm, Inst Biomed, E-08028 Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
Palomer, X:
Univ Barcelona, Fac Pharm, Pharmacol Unit, Dept Pharmacol & Therapeut, E-08028 Barcelona, Spain
Univ Barcelona, Fac Pharm, Inst Biomed, E-08028 Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
Blanco-Vaca, F:
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
Univ Autonoma Barcelona, Servei Bioquim, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Inst Recerca, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Hosp Santa Crue & San Pau, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain
Escola-Gil, JC:
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
Univ Autonoma Barcelona, Servei Bioquim, E-08193 Barcelona, Spain
Univ Autonoma Barcelona, Inst Recerca, E-08193 Barcelona, Spain
Sanchez, RM:
Univ Barcelona, Fac Pharm, Pharmacol Unit, Dept Pharmacol & Therapeut, E-08028 Barcelona, Spain
Univ Barcelona, Fac Pharm, Inst Biomed, E-08028 Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
Laguna, JC:
Univ Barcelona, Fac Pharm, Pharmacol Unit, Dept Pharmacol & Therapeut, E-08028 Barcelona, Spain
Univ Barcelona, Fac Pharm, Inst Biomed, E-08028 Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
Vazquez-Carrera, M:
Univ Barcelona, Fac Pharm, Pharmacol Unit, Dept Pharmacol & Therapeut, E-08028 Barcelona, Spain
Univ Barcelona, Fac Pharm, Inst Biomed, E-08028 Barcelona, Spain
Inst Salud Carlos III, Ctr Invest Biomed Red Diabet & Enfermedades Metab, Barcelona, Spain
Bronze
|